✦ LIBER ✦

Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia : A population-based cohort study in Sweden

✍ Scribed by Anand P. Chokkalingam; Olof Nyrén; Jan-Erik Johansson; Gloria Gridley; Joseph K. McLaughlin; Hans-Olov Adami; Ann W. Hsing

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 91 KB
Volume: 98
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.11710

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

Pathologically, benign prostatic hyperplasia (BPH) is not considered a precursor for prostate carcinoma. However, because the two conditions share not only a similar hormonal environment within the prostate but also several common risk factors, it is possible that men with BPH may be at increased risk of prostate carcinoma due to these shared factors.

METHODS

To elucidate this further, the authors used Swedish nationwide population‐based record‐linkage data to assess prostate carcinoma risk up to 26 years after the diagnosis of BPH among 86,626 men.

RESULTS

Overall, relative to the general population, patients with BPH experienced little, if any, excess risk of prostate carcinoma (2% excess incidence after 10 years of follow‐up). However, patients with BPH with and without surgical intervention experienced different prostate carcinoma risk patterns. Those undergoing transvesicular adenomectomy had a significant 22% lower incidence and a 23% lower mortality after the first 5 years of follow‐up and those undergoing transurethral resection had a significant 10% higher incidence but a 17% lower mortality. In contrast, after the first 5 years, patients with BPH who did not receive surgical intervention experienced significant excesses of both prostate carcinoma incidence (18%) and mortality (77%).

CONCLUSIONS

The differences in prostate carcinoma incidence and mortality by BPH treatment type suggest that factors related to treatment or health reasons underlying the selection of treatment influence subsequent prostate carcinoma risk. Further studies are needed to confirm the minimal excess risk of prostate carcinoma among BPH patients overall and the possible impact of BPH treatment methods on subsequent prostate carcinoma risk. Cancer 2003. Published 2003 by the American Cancer Society.

DOI 10.1002/cncr.11710

📜 SIMILAR VOLUMES

CYP17 polymorphisms in relation to risks

CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China

✍ M. Patricia Madigan; Yu-Tang Gao; Jie Deng; Ruth M. Pfeiffer; Bao-Li Chang; Siqu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB 👁 1 views

## Abstract Because androgens likely play a key role in prostate growth and prostate cancer development, variants of genes involved in androgen biosynthesis may be related to prostate cancer risk. The enzyme P450c17α, encoded by the __CYP17__ gene, catalyzes the conversion of progesterone and pregn

Risk of Hodgkin's disease subsequent to

Risk of Hodgkin's disease subsequent to tonsillectomy: A population-based cohort study in Sweden

✍ Kai-Li Liaw; Johanna Adami; Gloria Gridley; Olof Nyren; Martha S. Linet 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 33 KB 👁 2 views

Although some studies have linked excess of Hodgkin's disease (HD) to tonsillectomy, the findings have not been consistent. In particular, risk of HD by age at tonsillectomy has not been fully evaluated, despite the notable change in immunologic function of the tonsils between childhood and adulthoo

Survival in prostate carcinoma—Outcomes

Survival in prostate carcinoma—Outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up : Results from three counties in the population-based National Prostate Cancer Registry of Sweden

✍ Gunnar Aus; David Robinson; Johan Rosell; Gabriel Sandblom; Eberhard Varenhorst 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND To decide on screening strategies and curative treatments for prostate carcinoma, it is necessary to determine the incidence and survival in a population that is not screened. ## METHODS The 15‐year projected survival data were analyzed from a prospective, complete, pop

Isoflavone consumption and subsequent ri

Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women

✍ Norie Kurahashi; Manami Inoue; Motoki Iwasaki; Yasuhito Tanaka; Masashi Mizokami 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 96 KB 👁 2 views

## Abstract The incidence of hepatocellular carcinoma (HCC) is much higher in men than in women. Several experiment and epidemiological studies have suggested that estrogen might play an inhibitory role in the development of HCC. Because isoflavones have a similar structure as 17β‐estradiol and app

Reduced risk of prostate cancer in men w

Reduced risk of prostate cancer in men who are childless as compared to those who have fathered a child: A population based case-control study

✍ Aleksander Giwercman; Lorenzo Richiardi; Magnus Kaijser; Anders Ekbom; Olof Akre 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 68 KB 👁 2 views

## Abstract Androgens are believed to play a major role in the etiology of prostate cancer, but studies of sex‐hormone exposure in relation to risk for prostate cancer have been inconclusive. Male fertility may be an indicator of long‐term androgen status. To study the role of testicular function i